71.70
전일 마감가:
$70.73
열려 있는:
$71.02
하루 거래량:
7.44M
Relative Volume:
0.80
시가총액:
$243.07B
수익:
$43.59B
순이익/손실:
$15.04B
주가수익비율:
21.23
EPS:
3.3766
순현금흐름:
$10.74B
1주 성능:
+11.49%
1개월 성능:
+6.46%
6개월 성능:
-18.49%
1년 성능:
-43.92%
노보 노디스크 Stock (NVO) Company Profile
NVO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
NVO
Novo Nordisk Adr
|
71.70 | 314.28B | 43.59B | 15.04B | 10.74B | 3.3766 |
![]()
LLY
Lilly Eli Co
|
812.69 | 723.06B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
168.30 | 407.97B | 90.63B | 22.66B | 16.40B | 9.35 |
![]()
ABBV
Abbvie Inc
|
190.28 | 337.08B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
117.70 | 227.39B | 55.19B | 13.65B | 16.81B | 6.86 |
노보 노디스크 Stock (NVO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2025-03-13 | 업그레이드 | Kepler | Hold → Buy |
2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
2025-01-06 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
2024-05-30 | 개시 | Goldman | Buy |
2024-04-12 | 개시 | BMO Capital Markets | Outperform |
2024-01-23 | 개시 | Morgan Stanley | Overweight |
2024-01-16 | 재개 | UBS | Neutral |
2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
2023-10-02 | 개시 | Argus | Buy |
2023-07-14 | 개시 | HSBC Securities | Buy |
2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2021-01-15 | 개시 | Deutsche Bank | Buy |
2020-09-29 | 개시 | Berenberg | Hold |
2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
2020-05-04 | 개시 | Cowen | Market Perform |
2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
2018-12-11 | 재개 | Jefferies | Hold |
2018-10-09 | 개시 | Guggenheim | Buy |
2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HIMS - GlobeNewswire Inc.
Hims & Hers Health, Inc. Sued for Securities Law Violations - GlobeNewswire Inc.
HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
European ADRs Inch Higher As Drugmakers Shine - Finimize
Novo Nordisk’s GLP-1 Reign Faces New Pressures In 2025 - Finimize
HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
NVO’s 2025 Market Dance: Down -51.70% – Time to Invest? - investchronicle.com
Novo Nordisk's Cardiometabolic Foundation Supports Wide Moat - Morningstar
Novo Nordisk: Navigating Challenges to Dominate Diabetes and Obesity Therapies - AInvest
The Skinny On Novo Nordisk: This Slimmed-Down Stock May Be Worth A... Shot - Finimize
NVO’s Stock Woes: Down -31.04% in 6 Months, Down -31.04% in Just 5 Days - investchronicle.com
European Stocks Shine As ADRs Climb Higher - Finimize
After ousting CEO, Novo Nordisk reclaims crown as largest European company - MSN
Why Novo Nordisk Stock Just Popped - Barchart.com
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
European ADRs Show Resilience In US Market - Finimize
Novo Nordisk Faces Obesity Competition, but Innovation Still Warrants a Wide Moat - Morningstar
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize
What Did We Find About Insider Trading At Novo Nordisk ADR (NYSE: NVO)? - Stocksregister
European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):